Kallyope
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kallyope sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,751 sponsors by registered trial count).
Kallyope: 8 sponsored US clinical trials, 1 recruiting.
Kallyope sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes Mellitus in Obese, with 1 trials.
Upper-quartile sponsor footprint
Kallyope sits in the upper quartile of the sponsor corpus (#1,604 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07645924
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07674654
A Study of K-645 in the Treatment of Multiple Migraine Attacks
NCT07116499
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
NCT06848075
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
NCT06305351
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
NCT06019559
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
NCT05890950
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers
NCT05900531
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Kallyope pipeline
1 recruiting of 8 indexed (13% open); 5 completed (63%).
Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Type 2 Diabetes Mellitus in Obese (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.